

Fierce Biotech names Accent Therapeutics as one of its “Fierce 15” biotech companies of 2020

[Visit the Accent Therapeutics website](#)

Fierce Biotech names Accent Therapeutics as one of its “Fierce 15” Biotech Companies of 2020

Lexington, Mass. - September 28, 2020 – Accent Therapeutics today announced that it has been named by Fierce Biotech as one of 2020’s Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in the industry.

Accent is a leader in the development of small molecule therapies that selectively inhibit RNA-modifying proteins (RMPs) that drive cancer. By targeting RMPs, the company is taking a novel approach to unlocking the potential of RNA biology by targeting enzymes responsible for post-transcriptional chemical modifications of RNA. Accent is developing a rich pipeline of oncology-focused therapies in a new class of medicines that target RMPs.

“We are honored to be recognized by FierceBiotech as a leader in the biotech landscape, pursuing novel RMP-targeted therapies to bring new and potentially life-changing medicines to patients,” said Shakti Narayan, Chief Executive Officer, Accent Therapeutics. “This recognition is a tribute to our team’s fierce commitment to giving patients living with cancer greater hope, fewer burdens and the promise of a life beyond disease.”

The Fierce 15 celebrates the spirit of being “fierce” – championing innovation and creativity, even in the face of intense competition. This is Fierce Biotech’s 18th annual Fierce 15 selection.

“The 2020 Fierce 15 comes at a time when the world is focused on a pandemic, but even as coronavirus remains a threat, patients with cancer, rare diseases and other disorders still need treatment,” FierceBiotech Senior Editor Ben Adams said. “This year, we’ve chosen from a diverse range of those fighting COVID, as well as those fighting longer term plagues against our biology,” Adams said.

An internationally recognized daily report reaching a network of over 285,000 biotech and pharma industry professionals, Fierce Biotech provides subscribers with an authoritative analysis of the day’s top stories. Every year Fierce Biotech evaluates hundreds of private companies from around the world for its annual Fierce 15 list, which is based on a variety of factors such as the strength of its technology, partnerships, venture backers and a competitive market position.

About Accent Therapeutics

Accent Therapeutics is a biopharmaceutical company developing oncology-focused, small molecule therapies in the emerging field of RNA modification. This field of biology encompasses post-transcriptional chemical modifications of RNA that provide cells with a unique mechanism for regulating proteins critical for cellular growth and differentiation. By targeting cancer-linked RNA-modifying proteins (RMPs) with precision therapies, the Company aims to translate extraordinary science into life-changing therapies for patients. For more information, please visit www.accenttx.com.

About Fierce Biotech

Fierce Biotech is the biotech industry's daily monitor, an email newsletter and web resource providing the latest biotech news, articles, and resources related to clinical trials, drug discovery, FDA approval, FDA regulation, patent news, pharma news, biotech company news and more. More than 150,000 top biotech professionals rely on Fierce Biotech for an insider briefing on the day's top stories. Signup is free at www.fiercebiotech.com/signup.

Contacts

Fierce Biotech

Rebecca Willumson
(202.824.5050)

rwillumson@questex.com

Spectrum Science Communications

Madelyn Parks
(312.635.6286)

mparks@spectrumscience.com